
Ignacio Melero , MD, PhD, is a full professor of immunology at the University of Navarra and co-director of the Department of Immunology and Immunotherapy at the Clínica Universidad de Navarra. He is widely recognized for his pioneering work in cancer immunotherapy, particularly on immunostimulatory monoclonal antibodies and co-stimulation of antitumor immune responses.
He spent three years conducting research at Bristol-Myers Squibb in Seattle, collaborating with leading scientists such as Lieping Chen and Karl Hellström. Since returning to Spain in 1998, he has led a multidisciplinary team at CIMA and the Clínica Universidad de Navarra, focusing on cell-based immunotherapy, gene therapy, and monoclonal antibodies. Prof. Melero has served as principal investigator in over 40 clinical trials in immunotherapy, sponsored by both pharmaceutical companies and academic institutions.
He is a scientific editor for several prestigious journals, including Clinical Cancer Research, Cancer Discovery, and Journal for Immunotherapy of Cancer. He sits on multiple international scientific advisory boards, including those of Institut Curie (Paris), Gustave Roussy, the Netherlands Cancer Institute (NKI), and the Biomedical Research Institute of Granada. In 2023, he was appointed Kidani Professor of Cancer Immuno-Therapeutics at the University of Oxford.
He has published more than 350 scientific articles and supervised over 16 PhD theses, many of which have received awards for excellence. In 2024, he was awarded a prestigious ERC Advanced Grant from the European Union for his research on mRNA-based immunotherapies.